Hindawi Journal of Immunology Research Volume 2019, Article ID 2070562, 2 pages https://doi.org/10.1155/2019/2070562

## Corrigendum

## Corrigendum to "Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models"

Qing Zhang, Haixu Zhang, Qing Ding, Hongyan Liu, Huizhong Li, Hailong Li, Mengmeng Lu, Yangna Miao, Liantao Li, and Junnian Zheng, Hailong Li, Hailong

Correspondence should be addressed to Liantao Li; liliantao@xzhmu.edu.cn and Junnian Zheng; jnzheng@xzhmu.edu.cn

Received 23 December 2018; Accepted 3 January 2019; Published 27 March 2019

Copyright © 2019 Qing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled "Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models" [1], there was a typographical error in Figure 4(b) where the label of the statistical difference symbol should be corrected as follows:

<sup>&</sup>lt;sup>1</sup>Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

<sup>&</sup>lt;sup>2</sup>The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, Jiangsu 215600, China

<sup>&</sup>lt;sup>3</sup>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China




FIGURE 4: Therapeutic efficacy of EpCAM-specific CAR-NK-92 cells combined with regorafenib for human colorectal cancer xenografts established with HCT-8 cells. (a) Schematic diagram showing the treatment program of the mice. (b) The tumor growth curves during the experiment. (c) Luminescence images showing the tumor size at the end of the treatment. (d) Tumor weight at the end of treatment. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.

## References

[1] Q. Zhang, H. Zhang, J. Ding et al., "Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models," *Journal of Immunology Research*, vol. 2018, Article ID 4263520, 11 pages, 2018.